Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Bristol-Myers Squibb Co (NYSE: BMY) closed the day trading at $44.12 down -5.30% from the previous closing price of $46.59. In other words, the price has decreased by -$5.30 from its previous closing price. On the day, 21.68 million shares were traded. BMY stock price reached its highest trading level at $46.8616 during the session, while it also had its lowest trading level at $44.0.
Ratios:
For a better understanding of BMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.86. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.28. In the meantime, Its Debt-to-Equity ratio is 2.95 whereas as Long-Term Debt/Eq ratio is at 2.73.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.
Jefferies Upgraded its Hold to Buy on December 16, 2024, while the target price for the stock was maintained at $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 09 ’25 when Hickey Benjamin sold 97 shares for $38.01 per share. The transaction valued at 3,702 led to the insider holds 0 shares of the business.
Hirawat Samit bought 4,250 shares of BMY for $202,215 on Apr 25 ’25. The EVP,Chief Med.Offr.,Drug Dev. now owns 83,513 shares after completing the transaction at $47.58 per share. On Feb 20 ’25, another insider, BOERNER CHRISTOPHER S., who serves as the Chief Executive Officer of the company, bought 2,000 shares for $55.05 each. As a result, the insider paid 110,096 and bolstered with 104,626 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 89787727872 and an Enterprise Value of 129335762944. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.56, and their Forward P/E ratio for the next fiscal year is 7.27. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.88 while its Price-to-Book (P/B) ratio in mrq is 5.16. Its current Enterprise Value per Revenue stands at 2.715 whereas that against EBITDA is 6.745.
Stock Price History:
The Beta on a monthly basis for BMY is 0.38, which has changed by 0.00022673607 over the last 52 weeks, in comparison to a change of 0.11241627 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $39.35. The 50-Day Moving Average of the stock is -18.61%, while the 200-Day Moving Average is calculated to be -18.60%.
Shares Statistics:
Over the past 3-months, BMY traded about 14.49M shares per day on average, while over the past 10 days, BMY traded about 18092190 shares per day. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.08% of the company’s shares, while institutions hold 82.95% stake in the company. Shares short for BMY as of 1745971200 were 37123977 with a Short Ratio of 2.56, compared to 1743379200 on 29399379. Therefore, it implies a Short% of Shares Outstanding of 37123977 and a Short% of Float of 1.83.
Dividends & Splits
BMY’s forward annual dividend rate is 2.44, up from 2.44 a year ago. Against a Trailing Annual Dividend Yield of 0.052371755The stock’s 5-year Average Dividend Yield is 3.55.
